Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma

摘要

Background Intra-arterial chemotherapy (IAC) for retinoblastoma has been documented as causing visual loss and ocular motility problems. A lack of safety data has precluded its acceptance in all centres.